Skin cancer is the most common cancer in the U.S., with more than five million non-melanoma cases, overwhelmingly basal cell carcinomas, diagnosed annually. Aging populations, increased sun exposure, and rising detection rates are driving demand for treatment. Against this backdrop, Medicus Pharma (NASDAQ: MDCX) emerges as a compelling small-cap opportunity. The company is developing SkinJect(TM), a patented dissolvable microneedle patch delivering chemotherapy directly into tumors. If successful, it could provide a lower-cost, non-surgical alternative to conventional skin-cancer surgery, potentially tapping a market expected to nearly double to nearly $6 billion by 2030.
Medicus Pharma is advancing programs across three continents, with multiple mid-stage trials and a recently expanded pipeline through acquisition, building the foundation for long-term value creation. The pace of 2025 updates reflects a management team aggressively advancing assets and expanding its clinical footprint. For investors willing to accept biotech risk, Medicus sits at the intersection of non-invasive treatment for common cancers, a first-in-market hormonal therapy for cardiovascular-high-risk prostate cancer, and strategic collaborations that may open new modalities and markets.
A Novel Non-Surgical Approach to Treating Basal Cell Carcinoma
The centerpiece of Medicus’ pipeline is SkinJect(TM), designed to deliver doxorubicin directly into BCC tumors. The approach aims to provide a noninvasive alternative to Mohs surgery, which, while effective, can be costly, painful, and sometimes inaccessible, particularly for elderly or medically fragile patients.
Phase 1 (SKNJCT-001), completed in 2021, met safety and tolerability endpoints, with six of 13 participants showing complete histological response.
Phase 2 (SKNJCT-003, U.S.) has randomized over 75% of planned participants; interim results suggest more than 60% clinical clearance. The study expanded from 60 to 90 patients.
U.K. expansion, approved in November 2025, strengthens recruitment and geographic reach.
SKNJCT-004 (UAE) is underway at six sites led by Cleveland Clinic Abu Dhabi.
These programs position Medicus as one of the few companies pursuing multi-regional clinical development for non-surgical BCC therapy.
Strategic Moves Strengthening SkinJect
In October 2025, Medicus partnered with the Gorlin Syndrome Alliance to create a framework for compassionate and expanded-access use. Patients with Gorlin syndrome develop hundreds of BCC lesions over their lifetimes, making a repeatable non-surgical therapy particularly appealing, while real-world datasets may support regulatory filings.
In November 2025, Medicus applied for the FDA Commissioner’s National Priority Voucher (CNPV) designation, a pathway to accelerate approval for therapies addressing major U.S. public-health priorities. Medicus asserts SkinJect meets multiple criteria, including addressing a major cancer burden, offering an accessible surgical alternative, supporting domestic manufacturing, and fulfilling unmet needs for rare-disease populations.
Pipeline Expansion Through Teverelix Acquisition
In 2025, Medicus acquired Antev Limited, a UK-based biotech developing Teverelix trifluoroacetate (Teverelix TFA), a next-generation GnRH antagonist. Unlike conventional agonists, Teverelix suppresses sex hormones without an initial testosterone surge, reducing cardiovascular risk. Target indications include advanced prostate cancer patients with cardiovascular risk and patients experiencing acute urinary retention relapse (AURr).
Phase 1 in 48 volunteers showed rapid testosterone suppression with good tolerability.
Phase 2a (2023) met its primary endpoint, achieving a 97.5% probability of castration-level testosterone suppression. The FDA approved Phase 2b trial designs for both APC and AURr indications.
With a combined market opportunity of ~$6 billion, Teverelix provides a second late-stage asset with first-in-market potential.
Strengthened Balance Sheet and Leadership
Medicus reported $8.7 million in cash at the end of Q3 2025, supported by $10.4 million in recent financings. Operating expenses reflect global clinical expansion and Antev integration. Leadership continuity improved with Carolyn Bonner as President and CFO, bringing nearly 20 years of healthcare and life sciences experience. Her dual role may streamline financial planning, capital-market strategy, and cross-functional execution.
Why MDCX is Worth Watching
Medicus Pharma (NASDAQ: MDCX) is accelerating across multiple fronts: global clinical programs, strategic acquisitions, regulatory tailwinds, and rare-disease initiatives. For investors seeking early-stage biotech exposure with multiple catalysts, Medicus Pharma (NASDAQ: MDCX) offers differentiated opportunities in dermatologic and prostate oncology. Updates from SKNJCT-003, UAE and U.K. expansions, early Teverelix trial results, and FDA feedback on the CNPV application could drive steady news flow into 2026. If execution continues at this pace, MDCX could attract broader investor attention as its clinical story matures.